Side-by-side · Research reference

EpitalonvsVilon

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticAUTO-DRAFTED8/37 cited

BAnimal-StrongHUMAN-REVIEWED13/49 cited

Epitalon

Pineal bioregulator · Telomerase activator

5–10 mgPer cycle doseKhavinson 2003

HumanMechanisticKhavinson 2003

HoursHalf-life (est)

SQ or IM · Abdomen · Daily for 10–20 days

Vilon

Khavinson Bioregulator · Dipeptide

2 AADipeptide

T-helperStimulatesLinkova 2011

MouseModel basisKhavinson 2002

Literature lacks standardised clinical route

01Mechanism of Action

Parameter

Epitalon

Vilon

Primary target

Telomerase activity (proposed); pineal melatonin axis modulationKhavinson 2003

Immune cell differentiation pathways, chromatin modification

Pathway

Activation of telomerase reverse transcriptase (hTERT) in somatic cells; pineal-axis modulation supports endogenous melatoninKhavinson 2003

Vilon → Thymocyte sphingomyelinase activation → T-helper & cytotoxic T-cell differentiation; epigenetic suppression of aging markers (CCL11, HMGB1)

Downstream effect

Telomere elongation, improved sleep architecture, reported lifespan extension in aged miceKhavinson 2003

Enhanced T-cell differentiation (CD4+, CD8+, B-cells), thymocyte proliferation, modulated IL-1β comitogenic activity, proposed chromatin decondensation in aged lymphocytesLinkova 2011 Khavinson 2002 Lezhava 2023

Feedback intact?

—

Unknown — no HPA/HPG axis data

Origin

Synthetic 4-AA peptide derived from epithalamin (a natural pineal extract)Khavinson 2003

Synthetic dipeptide derived from Khavinson thymic peptide extraction studies (Thymalin fraction)Morozov 1997

Antibody development

—

02Dosage Protocols

Parameter

Epitalon

Vilon

Standard dose

5–10 mg / day for 10–20 days, 1–2× per yearKhavinson 2003

Anecdotal community protocol. Russian clinical literature uses similar cycling.

No clinical standard — literature lacks human dosing

Russian practice: often combined with other Khavinson peptides; no FDA/EMA trials.

Frequency

Once daily during a cycle

Unknown — literature does not specify chronic administration protocols

Lower / starter dose

2.5 mg / day

—

Evidence basis

In-vitro telomerase + Russian clinical trialsKhavinson 2003

Mouse / in vitro only

Duration

10–20 day cycles, 1–2× per year

Not characterised in humans

Reconstitution

Bacteriostatic water

—

Timing

Pre-sleep preferred (pineal alignment)

—

Half-life

Hours (estimated)

Not published — dipeptides typically <10 min plasma t½

Animal model dose

—

In vitro: 0.01–10 μg/mL culture medium (mouse thymocytes)

Not translatable to human mg/kg without pharmacokinetic data.

Route

—

Likely SQ or oral (Khavinson school uses both); no published ROA validation

04Side Effects & Safety

Parameter

Epitalon

Vilon

Injection site reaction

Mild irritation

—

Sleep architecture

Improved subjective sleep quality (anecdotal)

—

Cancer risk

Theoretical via telomerase activation in pre-malignant cells

—

Long-term safety

Limited Western RCT data

—

Pregnancy / OB

Avoid

—

Antibody formation

Not reported

Not reported; dipeptides generally low immunogenicity

Human safety data

—

Absent from PubMed-indexed literature

Theoretical risk

—

Immune hyperactivation in autoimmune-prone individuals (T-cell differentiation enhancement)

Animal models

—

No adverse effects noted in mouse thymocyte or pineal lymphoid cultures

Absolute Contraindications

Epitalon

·Pregnancy / breastfeeding
·Active malignancy or pre-malignant state

Vilon

·Active autoimmune disease (theoretical — no clinical data)

Relative Contraindications

Epitalon

·Family history of cancer

Vilon

·Pregnancy / lactation (no safety data)
·Acute infection with cytokine storm risk (immune modulation unknown)

05Administration Protocol

Parameter

Epitalon

Vilon

1. Reconstitution

Add 1–2 mL bacteriostatic water to 10 mg vial → 5–10 mg/mL.

No clinical protocols exist in Western peer-reviewed literature. Russian gerontological practice may use 1–10 mg ranges, but dosing is empirical.

2. Injection site

SQ — abdomen preferred. Rotate sites.

Subcutaneous injection (common for Khavinson peptides) or oral (some bioregulators reportedly active orally due to small size). No validated ROA.

3. Timing

Pre-sleep preferred to align with pineal axis.

Unknown — no circadian or meal-timing data. Khavinson school often recommends morning administration.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

Likely lyophilised powder, refrigerated. Reconstitution protocols not published.

5. Needle

29–31G, 4–8 mm insulin syringe.

—

06Stack Synergy

Epitalon

— no documented stacks

Vilon

+ Epitalon

Moderate

View Epitalon →

Both are Khavinson bioregulators targeting aging pathways. Epitalon (Ala-Glu-Asp-Gly) acts on telomerase and pineal function; Vilon on immune differentiation and chromatin decondensation. Combined in Russian gerontological protocols for multi-system aging intervention. Lezhava et al. (2023) tested both on aged lymphocyte chromatin, showing distinct epigenetic effects. Complementary, not synergistic in strict pharmacological sense.

Vilon: Empirical — no standard
Epitalon: Empirical — often 10 mg cycles
Frequency: Sequential or concurrent (literature ambiguous)
Primary benefit: Multi-system aging modulation (immune + pineal/circadian)

+ Thymalin

Weak

View Thymalin →

Thymalin is the parent polypeptide complex from which Vilon was isolated. Both target immune differentiation, but Thymalin is a complex mixture (multiple peptides), whereas Vilon is a purified dipeptide. Morozov & Khavinson (1997) described Vilon as a synthetic successor designed to replicate Thymalin's immunomodulatory effects with greater specificity. Redundant in practice; no published combination studies.

Vilon: No standard
Thymalin: 10–100 mg IM (polypeptide complex)
Primary benefit: Redundant — both target T-cell differentiation

Morozov 1997 Khavinson 2020